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All cancers carry somatic mutations. The patterns of
mutation in cancer genomes reflect the DNA damage
and repair processes to which cancer cells and their
precursors have been exposed. To explore these
mechanisms further, we generated catalogs of
somatic mutation from 21 breast cancers and
applied mathematical methods to extract mutational
signatures of the underlying processes. Multiple
distinct single- and double-nucleotide substitution
signatures were discernible. Cancers with BRCA1
or BRCA2 mutations exhibited a characteristic
combination of substitution mutation signatures
and a distinctive profile of deletions. Complex rela-
tionships between somatic mutation prevalence
and transcription were detected. A remarkable
phenomenon of localized hypermutation, termed
‘‘kataegis,’’ was observed. Regions of kataegis
differed between cancers but usually colocalizedwith somatic rearrangements. Base substitutions in
these regions were almost exclusively of cytosine
at TpC dinucleotides. The mechanisms underlying
most of these mutational signatures are unknown.
However, a role for the APOBEC family of cytidine
deaminases is proposed.
INTRODUCTION
Cancers carry somatic mutations. A small proportion are
‘‘drivers’’ that confer clonal advantage, are causally implicated
in oncogenesis, and have been positively selected during the
evolution of the cancer (Stratton, 2011; Stratton et al., 2009).
Driver mutations occur in the subset of genes known as cancer
genes. Through systematic sequencing of cancer genomes,
considerable advances have recently been made in the identifi-
cation of cancer genes, providing insights into mechanisms of
neoplastic transformation and targets for therapeutic interven-
tion (Stratton, 2011; Stratton et al., 2009). We have relatively
limited understanding, however, of the DNA damage and repair
processes that have been operative during the lifetime of theCell 149, 979–993, May 25, 2012 ª2012 Elsevier Inc. 979
patient and that are responsible for the somatic mutations that
underlie the development of all cancers in the first place.
Historically, analysis of mutation patterns to investigate under-
lying DNA damage and repair processes in human cancers has
predominantly been restricted to reporter cancer genes, notably
TP53. These studies have revealed that mutation patterns can
be related to carcinogen exposures and DNA repair processes.
For example, G>T/C>A transversions predominate in smoking-
associated lung cancer, a pattern compatible with DNA damage
induced by tobacco carcinogens such as benzo[a]pyrene
diolepoxide (Pfeifer et al., 2002). These mutations are enriched
at CpG dinucleotides and exhibit a transcriptional strand bias
reflecting past activity of transcription-coupled nucleotide exci-
sion repair (TCR) on bulky adducts of guanine caused by
tobacco carcinogens (Hainaut and Pfeifer, 2001). Similarly, in
UV-light-associated skin cancers, C>T and CC>TT transitions
are common. These occur at dipyrimidines, reflecting the forma-
tion of pyrimidine dimers following exposure of DNA to UV light
(Pfeifer et al., 2005) and also show transcriptional strand
bias due to the action of TCR on pyrimidine dimers. Further
examples of exogenous exposures leading to distinctive muta-
tional patterns include G>T transversions in aflatoxin B1-associ-
ated hepatocellular carcinomas (Mace´ et al., 1997) and A>T
transversions in urothelial tumors from patients exposed to aris-
tolochic acid (Nedelko et al., 2009).
Although these studies have been highly informative, they
have limitations. Because they depend upon driver mutations,
effects of selection have been superimposed upon mutational
patterns generated by DNA damage and repair processes.
Moreover, only a single mutation from each cancer sample is
usually incorporated into each data set. Thus, they have been
well placed to report strong exposures and dominant repair
processes operative across most cases of a particular tumor
type. However, where there is heterogeneity of mutational
process in a cancer class, a composite of different processes
will be reported.
The completion of the human genome sequence and the
advent of second-generation sequencing technology have over-
come historic limitations of scale, permitting sequencing of
whole cancer genomes (Berger et al., 2011; Chapman et al.,
2011; Ding et al., 2010; Lee et al., 2010; Ley et al., 2008; Mardis
et al., 2009; Shah et al., 2009; Tao et al., 2011), and generation of
comprehensive catalogs of somatic mutation (Pleasance et al.,
2010a; Pleasance et al., 2010b). Most somatic mutations in
cancers are thought to be ‘‘passenger’’ events that do not
contribute to cancer development. These bystanders bear the
imprints of the DNA damage and repair processes operative
during the development of the cancer, unmodified by selection.
The several hundreds to tens of thousands of somatic mutations
in each cancer, therefore, potentially allow much greater resolu-
tion of mutational patterns and insights into underlying muta-
tional processes.
Recent analyses of comprehensive mutational catalogs from
a malignant melanoma and a lung cancer illustrate the power
of this approach (Pleasance et al., 2010a; Pleasance et al.,
2010b). They revealed the characteristic mutational patterns
of UV light and tobacco carcinogens respectively (see above)
and provided strong evidence for the past activity of TCR. In980 Cell 149, 979–993, May 25, 2012 ª2012 Elsevier Inc.addition, G>T mutations in the lung cancer showed a preference
for CpG dinucleotides outside CpG islands, suggesting a role
for methylated cytosine because CpG islands are usually un-
methylated. Conversely, G>C mutations at CpG dinucleotides
were more prevalent within CpG islands suggesting that the
mutagen(s) underlying these mutations preferentially acted on
unmethylated DNA (Pleasance et al., 2010b). In the melanoma,
at least one additional mutational process characterized by
G>T changes and independent of UV light exposure was shown
to have been operative. In both cancers, mutations were more
common in poorly expressed than in highly expressed genes,
both on the transcribed and untranscribed strands. Indeed,
mutations were also found to be more prevalent at the 30 ends
of genes than at the 50 ends (Pleasance et al., 2010a). The
mechanisms underlying these expression-related phenomena
are unknown.
Compared to melanoma and lung cancer, the mutational
processes underlying other cancer types are poorly understood.
Therefore, in this study, we document essentially the full reper-
toire of somatic mutations of 21 breast cancers to investigate
the mutational mechanisms shaping these cancer genomes.
RESULTS
Sequencing of Breast Cancers
We sequenced the complete genomes of 21 primary breast
cancers and matched normal DNAs from the same individuals.
Cancers were typed for estrogen receptors (ER), progesterone
receptors (PR), and HER2, and included nine cases with germ-
line mutations in the breast cancer predisposition genes
BRCA1 (five) and BRCA2 (four) (Table S1A, available online).
Cancer and normal DNAs were sequenced to > 30-fold
coverage and analyzed to identify somatic base substitutions,
insertions, and deletions (indels); rearrangements; and copy
number changes. PD4120a was sequenced to 188-fold depth
to investigate temporal and clonal evolution (Nik-Zainal et al.,
2012). Using orthogonal sequencing technologies we estimated
the specificity of substitution-calling to be 92.1% (Table S1A).
All substitutions were therefore included in the analyses. For
indels and rearrangements only confirmed variants were
included (Table S1B). From 17 of the 21 casesmRNA expression
data were also obtained.
The Catalogue of Somatic Mutations from 21 Breast
Cancer Genomes
A total of 183,916 somatically acquired base substitutions were
identified (see Table S1B for hyperlinks). In protein coding
regions, there were 1,372 missense, 117 nonsense, 2 stop-
lost, 37 essential splice-site, and 521 silent mutations. Of the
2,869 indels identified, 2,233 were deletions, 544 insertions
and 92 complex. There were 21 coding indels, of which 15
were predicted to result in a translational frameshift and six
were in-frame. In addition, 1,192 structural variants (rearrange-
ments), 16 homozygous deletions, and 14 regions of increased
copy number (amplifications) were identified (Table S1C).
Likely driver substitutions and indels in cancer genes
were found in TP53, GATA3, PIK3CA, MAP2K4, SMAD4,
MLL2, MLL3, and NCOR1 (Table S1C). Amplification was
observed over cancer genes previously implicated in breast
cancer development including ERBB2, CCND1, MYC, MDM2,
ZNF217, and ZNF703 and a homozygous deletion involving
MAP2K4 was identified. All tumors derived from BRCA1 or
BRCA2 germline mutation carriers showed loss of wild-type
haplotypes at 17q21 or 13q12, respectively, as expected of
recessive cancer genes (Table S1B).
Extracting Mutation Signatures from Catalogues
of Somatic Mutation
The set of somatic mutations in a cancer genome is the aggre-
gate outcome of one or more mutational processes. Each
process leaves a mutation signature on the cancer genome
defined by the mechanisms of DNA damage and repair that
constitute it. The final catalog of mutations is determined by
the strength and duration of exposure to each mutational
process. We set out to extract the mutation signatures charac-
terizing the mutational processes operative in the 21 breast
cancers studied.
There was substantial variation between the cancers in the
numbers and relative contributions of each of the six classes of
base substitution (C>A, C>G, C>T, T>A, T>C, and T>G) (Fig-
ure 1A). To provide greater depth of insight into the operative
mutational processes, we incorporated the sequence context
in which mutations occurred, by considering the bases immedi-
ately 50 and 30 to each mutated base. Because there are six
classes of base substitution and 16 possible sequence contexts
for each mutated base there are 96 possible mutated trinucleo-
tides. We have represented the fraction of mutations at each of
the 96 mutated trinucleotides as a heat map for each cancer
and normalized it according to the prevalence of each trinucleo-
tide in the genome. The display therefore highlights mutational
signatures generated by processes that favor particular classes
of mutation and/or particular sequence contexts in which muta-
tions occur (Figure 1C).
Visual inspection of the 21 heatmaps provided evidence for
multiple independent mutational signatures and indicated that,
in most cancers, more than one process had been operative.
For example, overrepresentation compared to chance of C>T
substitutions at XpCpG triplets (C is the mutated base and X is
any base) was observed in all cancers, albeit to different extents.
The elevated C>T mutation rate at XpCpG trinucleotides is a
well-recognized mutational mechanism probably due to deami-
nation to thymine of methylated cytosines, which are usually at
XpCpGs (Waters and Swann, 2000). The role of methylated cyto-
sine is supported in our data by the higher frequency of C>T tran-
sitions at XpCpG triplets outside CpG islands (where most
XpCpGs are methylated) than inside (where most are unmethy-
lated) (OR 9.95; 95% CI 7.17–13.8; p < 0.0001). Subtler features
of this mutational signature were also apparent, notably the
influence of the base 50 to the mutated cytosine on the C>T
mutation rate (for example, see PD3905a). Although the
normalized heatmap representation emphasizes the ubiquitous
elevation of the C>T mutation rate at XpCpG trinucleotides, the
absolute number of these mutations is relatively modest
because of the general depletion of XpCpGs from the human
genome due to the activity of the same, or a similar, mutational
process in the germline over evolutionary time.There was also an overrepresentation of C>T, C>G and C>A
mutations at TpCpX trinucleotides in many breast cancers
and very pronounced in some (notably, PD4199a and P4120a).
In addition to the high proportion of T immediately 50 to the
mutated cytosine, the base immediately 30 to the mutated C
also appears to influence this mutational signature with greater
overrepresentation of TpCpA, TpCpT and TpCpG than of
TpCpC. We have previously reported this signature in breast
and other cancers (Greenman et al., 2007; Stephens et al.,
2005, 2012).
Application of Mathematical Approaches to Extract
Mutation Signatures
Although major features of some mutational signatures can be
discerned by visual inspection, a formal mathematical approach
is required to extract subtler elements and weaker signatures
and to assess the contribution of each mutational process to
the mutation set in each cancer. We employed a nonnegative
matrix factorization (NMF) and model selection approach (Berry
et al., 2007) to extract mutational signatures from the 21 cases.
NMF extracts interpretable features from complex multidimen-
sional data (Berry et al., 2007; Lee and Seung, 1999). For
example, application to images of faces yields familiar compo-
nents such as eyes, nose, and mouth (Lee and Seung, 1999).
Our desire to extract biologically meaningful mutational signa-
tures, as well as the intrinsic nonnegativity of the mutation spec-
trum data, renders NMF an appropriate choice for factorizing the
data from the 21 cases.
Evaluation of NMF decompositions (Berry et al., 2007)
(Extended Experimental Procedures and Figures S1A–S1C)
suggested that a best estimate of five biologically distinct muta-
tional signatures were present in the 21 cancers (named A–E,
Figure 2A). Each signature was characterized by a different
profile of the 96 potential trinucleotidemutations and contributed
to a different extent to each of the 21 cancers. Different combi-
nations of the five signatures account for the variation in the 21
mutational catalogs (Figure 1D).
Signature A was characterized by C>T mutations at XpCpG
trinucleotides but included other mutation classes making
smaller contributions (Figure 2A). Signature B was composed
predominantly of C>T, C>G and C>A mutations at TpCpX trinu-
cleotides. The dominant features of these two mutational signa-
tures were previously noted by scrutiny of the heatmaps (see
above). However, for each process NMF provided greater insight
into the relative contributions of all mutation classes.
NMF provided evidence for three additional mutational
processes. Signature C and Signature D both exhibited a rela-
tively even distribution of mutations across the 96 trinucleotides.
However, there were subtle differences. Signature Cwasmoder-
ately enriched for C>T, C>G and, to a lesser extent, C>A muta-
tions at XpCpG trinucleotides, whereas Signature D was not
(Figures 2A and S1D). In hindsight, an enrichment of C>G and
C>A mutations at XpCpG trinucleotides can be discerned in
some cancers in the heatmap (Figure 1C). Moreover, the
strength of this enrichment does not appear to be well correlated
with enrichment of C>T mutations at XpCpG trinucleotides,
suggesting that they are due to different processes, providing
the rationale for NMF to separate Signature C from Signature ACell 149, 979–993, May 25, 2012 ª2012 Elsevier Inc. 981
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Figure 1. Somatic Mutation Profiles of 21 Breast Cancers, Related to Table S1
Breast cancers grouped according to subtype on the far left.
(A) Base substitution mutation spectra. *Ultra-deep sequenced PD4120a has an alternative scale on the x axis (0 to 45,000).
(B) Mutation spectra of double substitutions from all 21 samples.
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(compare, for example, PD4006a and PD3945a in Figure 1C). In
Signature E the dominant feature was C>G mutations at TpCpX
trinucleotides. Signature E is therefore similar to Signature B, but
lacks the C>T mutations at TpCpX trinucleotides characteristic
of Signature B.
NMF will extract mutational patterns due to sequencing arti-
facts. We noted a signature characterized by T>G mutations at
GpTpX trinucleotides. This was not, however, reproduced in
somatic mutations verified by using another sequencing tech-
nology and transpired to be due to aberrant sequence phasing
at Ts following runs of Gs in the genome.
NMF can estimate the contribution of each mutational signa-
ture to the mutational catalog of each breast cancer. The results
indicate that multiple mutational processes contribute to most
cancers, although in some cases one process has been
dominant (Figure 1D). No correlation was found between the
presence of a particular somatically mutated gene and any of
these processes. We then performed unsupervised hierarchical
clustering by using the relative contributions of each of the five
signatures to each of the 21 mutational catalogs as features.
Interestingly, all nine breast cancers with BRCA1 or BRCA2
mutations clustered together (Figure 2B). This was predomi-
nantly due to a relatively substantial contribution by Signature
D and a relative deficiency of Signature A in these cancers.
Mutational Processes Generating Double-Nucleotide
Substitutions
By performing Monte Carlo simulations we showed that the
number of double-nucleotide substitutions (for example,
CpC>ApT) in each of the 21 cancer genomes was 75–11,000
fold higher than expected if single-nucleotide substitutions had
been randomly distributed (p < 0.001) (Table S1D). Thus,
a mutational process generating double-nucleotide substitu-
tions seems to be ubiquitous. Overall, the patterns of double-
nucleotide substitutions reflected those of single-nucleotide
substitutions in each cancer. However, in most cases there
was substantial enrichment of C>A substitutions as components
of double-nucleotide substitutions (Figure 1B) with the conse-
quent emergence of CpC>ApA as the most common class of
double-nucleotide substitution (Table S1E). Double-nucleotide
substitutions were distributed throughout the cancer genomes
without obvious evidence of further clustering.
Regional Hypermutation,Kataegis, Is Common in Breast
Cancer
We investigated the possibility of regional clustering of sub-
stitution mutations by constructing ‘‘rainfall plots’’ in which the
intermutation distance, the distance between each somatic
substitution, and the substitution immediately before it has
been plotted for eachmutation (Figures 3A–3C and S2). Mutation
clusteringwas commonly observed in the 21 breast cancers. The
mutational patterns within these clusters are outlined below by
using two cases as examples.(C) Genomic heatmap constructed from counts of each mutation-type at each mu
genome. Log-transformed values of these ratios have been plotted in the heatmap
the horizontal axis. Heatmap scale at the bottom.
(D) Proportion of the total substitutions contributed by each of the five mutationaThe largest regional cluster of mutations was found in a
breast cancer with a germline mutation in BRCA1, PD4107a,
which showed a markedly elevated mutation prevalence over a
14Mb region on chromosome 6 (Figure 3A). Themutationswithin
this cluster exhibited several remarkable features. First, there
was evidence of further clustering within the 14 Mb region (the
‘‘macrocluster’’), with heavily mutated stretches of genome of a
few hundred base pairs (‘‘microclusters’’) sometimes separated
by tens of kilobases without mutations (Figure 4A). Second,
substitutionswithin the regionwere characterized by adistinctive
mutational spectrum and sequence context (Figure 3D). Most
were C>T transitions at TpCpX trinucleotides. Third, examination
of individual sequence reads, which derive from individual DNA
molecules, showed that most mutations within microclusters
occurred in cis with respect to each other, i.e., were on the
same parental chromosome (Figure 4A). Fourth, mutations
were generally of the same type for long genomic distances
and then could switch to a different class. For example, in
PD4107a mutations were almost exclusively C>T (on the plus
chromosomal strand) for several megabases and then switched
to G>A (Figure 4B). This suggests that groups of mutations may
be generated on just one of the two DNA strands, perhaps simul-
taneously or in a processivemanner over a short time span. Fifth,
the cluster of mutations on chromosome 6 colocalizes with
a cluster of somatic genomic rearrangements (Figure 4A). Within
the hypermutated 14 Mb region, there were 17 genomic rear-
rangements but only seven in the remaining 157 Mb of chromo-
some 6. Most of these rearrangements were between different
locations within the chromosome 6 14 Mb region. Despite the
clear positional correlation between rearrangements and hyper-
mutation, at higher resolution mutation microclusters were
usually separated from the nearest rearrangement by many kilo-
bases. Finally, in PD4107a a much smaller mutation cluster with
similar mutational characteristics and associated with genomic
rearrangements was observed on chromosome 12.
An ER-positive breast cancer, PD4103a, also exhibited local-
ized hypermutation, but the pattern of mutation clustering
differed slightly from that in PD4107a (Figure 3B). There were
multiple mutation clusters involving chromosomes 3, 4, 8, 10,
11, 12, 20, and 21 each of which spanned shorter distances
than the major cluster in PD4107a. The clustered substitutions
in PD4103a included C>T transitions at TpCpX dinucleotides,
similar to PD4107a, but in addition a greater proportion of C>G
mutations at TpCpX trinucleotides. In other respects, notably
the mutations being in cis and showing a processive pattern,
there were many similarities (Figures 5A–5B). Mutation clusters
in PD4103a were also closely associated with somatic genomic
rearrangements that were all linked together by a web of inter-
chromosomal rearrangements (Figure 5C).
We have termed the presence of regional mutation clusters
kataegis (from Greek for shower or thunderstorm). Rainfall
plots revealed varying extents of kataegis in 13/21breast cancers
(PD4199a, PD4192a, PD4198a, PD4248a, PD4109a, PD4116a,tation context corrected for the frequency of each trinucleotide in the reference
. The 50 base to eachmutated base is shown on the vertical axis and 30 base on
l signatures, as identified by NMF analysis, for all 21 cancer genomes.
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AB
Figure 2. Five Mutational Signatures Extracted by NMF in 21 Breast Cancers, Related to Figure S1
(A) Fraction of contribution of each mutation-type at each context for the five mutational signatures identified by NMF analysis. The major components
contributing to each signature are highlighted with arrows.
(B) Cluster dendrogram generated by unsupervised hierarchical clustering based on contributions of the five mutational signatures identified by NMF to the 21
breast cancer genomes.PD3904a, PD3945a, PD4005a, PD4006a, PD4103a, PD4120a,
and PD4107a, see Figure S2), encompassing all subclasses of
the disease. In each case, the features were similar to those out-
lined forPD4107aandPD4103a. In some instances, kataegiswas
associated with rearrangements that had features of chromo-
thripsis (Stephens et al., 2011) (Figure 4D), but it also colocalized
with other rearrangement architectures. Previously published984 Cell 149, 979–993, May 25, 2012 ª2012 Elsevier Inc.mutation catalogs from a malignant melanoma and small cell
lung cancer did not show kataegis (Pleasance et al., 2010a,
2010b) (data not shown).
The pattern of C>T and C>G mutations at TpCpX trinucleo-
tides in kataegis is similar to that of mutational Signature B,
and to a lesser extent, Signature E (Figure 2A). Yet, in many
cancers with kataegis, Signatures B and E make only a small
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Figure 3. Kataegis, Regional Hypermutation of Base Substitutions, Related to Figure S2
(A) Rainfall plot of PD4107a. Mutations are ordered on the x axis from the first variant on the short arm of chromosome 1 to the last variant on the long arm of
chromosome X and are colored according to mutation-type. The distance between each mutation and the one prior to it (the intermutation distance) is plotted on
the vertical axis on a log scale. Most mutations in this genome have an intermutation distance of 105 bp to 106 bp. Mutations in a region of hypermutation
present as a cluster of lower intermutation distances.
(B) Rainfall plot for PD4103a demonstrating kataegis occurring at multiple loci through the genome.
(C) Rainfall plot for PD4085a, showing no kataegis.
(D) Plots of flanking sequence of all C>X mutations and C>X mutations within the regions of kataegis in PD4107a. Mutated base is at position 0 with ten bases of
flanking sequence provided, demonstrating a strong preference for T at the 1 position.
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Figure 4. Rainfall Plot for Chromosome 6 of PD4107a
(A) The x axis shows the genomic coordinates of the mutations. Rearrangements are presented as brown triangles (rearrs is an abbreviation for rearrangements).
The region of kataegis is highlighted at increasing resolution to demonstrate microclusters within the macrocluster. The processive nature of C>T mutations at
TpC context occurring in cis is seen in the lowest panel (G-browse image).
(B) Alternating processivity of kataegis in PD4107a. Long regions of C>T mutations are interspersed with regions of G>A mutations.
(C) Kataegis occurs with a variety of rearrangement architectures. Thick top line shows the copy number segments for the region of chromosome 6 of PD4107a.
Point mutations are shown in lower panel as black points. x axis reflecting genomic position and y axis represents variant allele fraction. The proportions of reads
derived from contaminating normal cells are depicted in gray and the fraction coming from each of the copies of that segment in the tumor cells are depicted by
the multiple bars from green to yellow to pink to white. Early mutations will be found relatively higher up these bars, whereas late ones will be seen down the
bottom of the variant allele fraction. Grey vertical lines represent rearrangements. Interconnecting lines indicate intrachromosomal rearrangements. On
a macroscopic scale, this demonstrates how kataegis can be associated with chromothripsis (within region 130–135 Mb) as well as other rearrangement
architectures.
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Figure 5. Processivity and Complex Coloc-
alization of Rearrangement Architecture
with Kataegis in PD4103a
(A) Stretches of C>T alternate with stretches of
G>A on chromosome 4 in PD4103a.
(B) Alternating C>G and G>C mutation on the
same chromosome in PD4103a.
(C) The complex web of rearrangements involving
8 chromosomes in PD4103a colocalizing with ka-
taegis.contribution to the genome-wide mutation catalog. Conversely,
Signature B dominates PD4199a (Figures 1A, 1C, and 1D)
despite relatively limited kataegis (Figure S2). Therefore,
intriguingly, a globally distributed and a localized form of the
mutational processes underlying these signatures may exist,
and the two forms may operate independently of each other.
The Relationship between Substitution Mutations
and Transcription
We next examined the relationship between transcription and
prevalence of somatic substitutions. First, we searched for
differences in the prevalence of mutations on the transcribed
and untranscribed strands (transcriptional strand bias) of protein
coding genes. A moderate degree of strand bias was detectable
for C>A/G>T transitions across the 21 breast cancer genomes
(p = 1.75 3 1015) and is present in almost all cases (Figure 6A).
This bias was characterized by fewer G>T mutations on tran-Cell 149, 979–9scribed than untranscribed strands. A
strand bias was also observed for T>G/
A>C mutations (p = 1.5 3 104) with
fewer T>G mutations on transcribed
than untranscribed strands. No evidence
of a transcriptional strand bias was
observed for C>G/G>C, C>T/G>A, T>A/
A>T or T>C/A>G mutations.
The best-recognized cause of tran-
scriptional strand bias is TCR that
removes nucleotides with bulky adducts
from the transcribed strands of genes.
Assuming that TCR is responsible for
the observed strand biases, the presence
of fewer G>T mutations on transcribed
than untranscribed strands would sug-
gest that bulky adduct damage to guanine
may be the cause of the observed muta-
tions. Similarly, the presence of fewer
T>G mutations on transcribed compared
to untranscribed strands would suggest
that there may have been bulky adduct
damage to thymine. The nature of these
ubiquitous mutagenic exposures in
breast cancer, which may conceivably
be of exogenous or endogenous origins,
is unknown. However, the hypothesis
that TCR is involved is currently un-
substantiated and it may ultimately tran-spire that other DNA repair, or indeed damage, processes
differentially affect the transcribed and untranscribed strands of
genes.
We next examined the relationship between levels of gene
expression and prevalence of somatic mutation. An inverse
correlation between substitution prevalence and gene expres-
sion was observed for C>A/G>T (p = 2.47 3 109), C>T/G>A
(p = 7.5 3 103), T>A/A>T (p = 1.09 3 106), and T>C/A>G
(p = 1.83 3 104) mutations for both transcribed and untran-
scribed strands (Figures 6 and S3A). No correlation was
observed for C>G/G>C or T>G/A>C mutations.
The results indicate that mutational processes characterized
by both transcriptional strand bias and expression-related muta-
tion prevalence are operative in breast cancer, similar to our
previous observations in melanoma and lung cancer. However,
T>G/A>C mutations exhibited a transcriptional strand bias
but not expression-related mutation prevalence. Conversely,93, May 25, 2012 ª2012 Elsevier Inc. 987
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Figure 6. Relationship between Mutation
Prevalence and Transcription and/or
Expression, Related to Figure S3
Mutation prevalence is expressed as the number
of mutations per Mb from 0 to 2 per Mb on the
vertical axis. Log 2 expression levels range from 6
to 12 on the horizontal axis. Lines are fitted curves
to the data for A and B.
(A) C>A mutations; and (B) T>A mutations. Breast
cancer samples without expression data are
shown in gray.
(C) Effect of distance from transcription start site
on mutation prevalence. Each dot represents a 1
kb bin at increasing distances from all transcription
start sites (TSS) up to 200 kb. The y axis shows the
percentage of genes in each bin carrying a somatic
mutation. The mutation prevalence increases as
distance increases from the TSS.
(D) This is particularly marked in the first 1 kb after
the TSS. Each dot represents a 100 bp bin.C>T/G>A, T>A/A>T, and T>C/A>G mutations showed expres-
sion-related mutational prevalence but no transcriptional strand
bias (Figure 6B and Figure S3A) suggesting that these two
features are independent.
Finally, we examined the relationship between distance from
the transcriptional start site (TSS) and mutation prevalence
in protein coding genes. There was evidence of increasing muta-
tion prevalence at increasing distance from the transcription
start site (Figure 6C), suggesting that the suppressive influences
of transcription upon mutagenesis described above wane as
proximity to the TSS decreases. This effect appears to be partic-
ularly pronounced in the first 1 kb from the TSS (Figure 6D). The
result confirms the observation previously made on UV light
induced C>T mutations in a melanoma.988 Cell 149, 979–993, May 25, 2012 ª2012 Elsevier Inc.Microhomology-Mediated
Deletions in BRCA1 and BRCA2
Mutant Cancers
Of the 2,869 validated somatic indels
from the 21 breast cancers, single-base
pair indels were the most common in
each case (Figure 7A). There was sub-
stantial variation in number and pattern
of indel, however, with more and larger
indels observed in BRCA1 and BRCA2
mutant cancers.
The sequences flanking each indel
were interrogated for the presence of
short tandem repeats or short stretches
of identical sequence at the breakpoints
(termed overlapping microhomology)
(Figure 7B). Repeat-mediated indels
were small (1–5 bp), present in all breast
cancers, and comprised both deletions
and insertions. Microhomology-mediated
indels were larger (up to 50bp), mainly
deletions and considerably more
common in cases with BRCA1 or
BRCA2 mutations (p = 2.2 3 1016).
Overlappingmicrohomology is often considered a signature of
nonhomologous end-joining (NHEJ) DNA double-strand break
(DSB) repair. The segments of microhomology probably mediate
alignment of the two DNA ends that are joined. Because BRCA1
and BRCA2 are involved in homologous recombination (HR)-
based DSB repair, the elevated frequency of microhomology-
mediated indels in BRCA1 or BRCA2 mutant cancers presum-
ably reflects usage of alternative methods of DSB repair in these
cancers (Figure 7C).
DISCUSSION
Catalogues of somatic mutation from 21 breast cancers have
yielded several insights into underlying mutational mechanisms.
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Figure 7. Somatic Mutation Profile of Indels
(A) The x axis shows indel size from 1–10 and all
larger indels between 11-50 bp in size grouped in
a single bin. The y axis shows the number in each
genome from 0–300.
(B) Frequency of indels by indel size. This
demonstrates how repeat-mediated indels are
usually of smaller size. From a Kolmogorov-Smir-
nov (K-S) test, the distribution of indel lengths for
repeats and microhomologies is significantly
different (p < 2.2 3 1016).
(C) Observed number of bases involved in micro-
homology at junction of indels versus expected
number of bases if microhomology occurred
simply by chance.Five independent single-nucleotide substitution processes
appear to have been operating, generating the observed varia-
tion in mutation numbers and patterns between cancers. The
processes appear to have been acting in combination, either
contemporaneously or during different phases of evolution of
the cancer clone (Nik-Zainal et al., 2012). Additional subtle
processes may exist, and sharper definition of currently charac-
terized processes may follow refinements of NMF and inclusion
of other mutational features in the models.
Signature A is likely mediated by deamination of 5-methyl-
cytosine at XpCpG trinucleotides leading to C>T transitions.
However, the mechanisms underlying the remainder are
currently unknown. Signature B, characterized by C>T, C>G,
and C>A substitutions at TpCpX trinucleotides, is responsible
for the overwhelming majority of mutations in certain cancer
samples and is present in this dominant form in approximatelyCell 149, 979–10% of ER-positive breast cancers (Ste-
phens et al., 2012). The mutational
patterns in Signatures C, D, and E have
not, to our knowledge, been previously
described.
A remarkable process generating
regional hypermutation, termed kataegis,
is frequently operative in breast cancer.
Regional clusters of mutations in cancer
have occasionally been observed in
experimental models, although not at
the mutation density observed here
(Wang et al., 2007). Mutations within
regions of kataegis bear similarities to
those in Signature B, notably the prepon-
derance of C>T and C>G substitutions at
TpCpX trinucleotides. Furthermore, they
are closely associated with regions of re-
arrangement and occur on the same
chromosome and chromosomal strand
over long genomic distances, suggesting
that they occur simultaneously or in
a processive manner over a short time
span (Chen et al., 2011).
On the basis of similarities to muta-
tional patterns observed in other biolog-ical contexts or in experimental systems, we propose that the
AID/APOBEC family of proteins may be implicated in kataegis
and/or in the mutational process underlying Signature B.
Although APOBEC1, the founding member of the AID/APOBEC
family, was first identified as an RNA-editing enzyme (Teng
et al., 1993) several members of the AID/APOBEC family
(including APOBEC1 itself) can deaminate cytosine to uracil
within DNA, acting as DNA mutators (Harris et al., 2002). AID
functions in antibody diversification, deaminating cytosine resi-
dues within the immunoglobulin loci in B lymphocytes thereby
triggering somatic hypermutation and class-switch recombina-
tion (reviewed in Longerich et al., 2006). There are seven APO-
BEC3 proteins in humans, with the prototype (APOBEC3G) as
well as several other APOBEC3s acting on lentiviral replication
intermediates constituting an innate pathway of antiretroviral
defense (Hultquist et al., 2011; Sheehy et al., 2002).993, May 25, 2012 ª2012 Elsevier Inc. 989
Although off-target deamination by AID is likely responsible for
the mutations and translocations seen in many B cell tumors
(reviewed in Nussenzweig and Nussenzweig, 2010), AID is
unlikely to account for the mutational signatures described
here because it exhibits a strong preference for deaminating
C residues flanked by a 50-purine (Pham et al., 2003). In contrast,
the Cs targeted in Signature B and kataegis are preceded by
a 50-T. However, APOBEC1 (when acting on DNA) and the APO-
BEC3 enzymes (apart from APOBEC3G) favor C residues
flanked by a 50-T (Harris et al., 2002; Hultquist et al., 2011).
Furthermore, transgenic overexpression of APOBEC1 is associ-
ated with cancer development (Yamanaka et al., 1995) and
enforced overexpression of APOBEC3A causes genomic
damage and mutation (Landry et al., 2011; Stenglein et al.,
2010; Suspe`ne et al., 2011). Thus APOBEC1 and some APO-
BEC3s are attractive candidates for the mechanisms underlying
kataegis and/or mutation Signature B. Thus far, we have
not observed a clear correlation between overexpression of
a member of the AID/APOBEC family and kataegis or Signature
B, although some key samples lack expression data.
Signature E also exhibits mutations at TpCpX trinucleotides,
but is characterized by a much lower fraction of C>T mutations
than Signature B. It is possible that both result from cytidine to
uracil deamination by an APOBEC family member, but that the
different signatures are sequelae of different repair mechanisms
following the deamination step. C>T transitions may simply
result from DNA replication across uracil. However, if uracil
is excised by uracil-DNA glycosylase (UNG) as part of base
excision repair (BER), an abasic site is generated (Wilson and
Bohr, 2007). The partiality for C>G transversions in Signature E
may reflect preferential insertion of cytosine opposite such
an UNG-mediated abasic site. The propensity to introduce
cytosine opposite an abasic site is characteristic of REV1 trans-
lesion polymerase, which is known to function in BER (Jansen
et al., 2006; Ross and Sale, 2006). Thus, Signature B may
be caused by a combination of replication and BER, whereas
Signature E may be the imprint of the almost exclusive activity
of BER on uracil.
Further studies are required to explore whether and how AID/
APOBEC family members contribute to mutagenesis in cancer. If
they are implicated in kataegis, current understanding of the
mode of action of AID in immunoglubulin gene somatic hypermu-
tation and class switch recombination would suggest that their
primary effect is through deamination of cytidine to uracil, with
substitutions and rearrangements both consequent upon this
initiating event. If so, an important remaining question is how
the activity of the enzymes is targeted to the regions of kataegis.
Furthermore, if the same enzymes from the AID/APOBEC family
are also involved in mutation Signatures B and possibly E, it
remains to be understood how their activities can be unleashed
upon the whole genome without apparent relation to the pres-
ence of rearrangements, as opposed to being regionally targeted
in the vicinity of rearrangements in kataegis.
Other mechanisms and enzymatic activities may, however, be
responsible for kataegis. If so, the question of which constitutes
the primary set of lesions, the rearrangements, or the substitu-
tions observed in kataegis, remains to be addressed. If a
stochastic event in a cell nucleus results in a DNADSB and repair990 Cell 149, 979–993, May 25, 2012 ª2012 Elsevier Inc.of this break is associated with accumulation of substitutions in
the vicinity of the consequent rearrangement, this could provide
an explanation for the regional targeting of kataegis. Indeed,
such mechanisms have been reported in yeast (Deem et al.,
2011; Hicks et al., 2010).
In all the breast cancers, double-nucleotide substitutions were
much more common than expected by chance adjacency of
single-nucleotide substitutions, suggesting the existence of
one or more biological processes responsible for their presence.
Currently, the best-characterized double-nucleotide substitu-
tions in human cancer are the CpC>TpT mutations found in
skin tumors, which are generally attributed to the pyrimidine
dimers generated by UV light exposure. In principle, the dinucle-
otide mutations observed in breast cancer could also be due to
exposures with a propensity to damage adjacent DNA bases.
However, other mechanisms are also plausible, for example
error prone polymerases that have a higher risk of misincorpora-
tion at a base adjacent to one that is damaged.
BRCA1 and BRCA2 are implicated in HR-based DNA repair
processes. The distinctive profile of small deletions with rear-
rangement breakpoints showing overlapping microhomology in
BRCA1 and BRCA2 mutant cancers is therefore compatible
with these processes being defective and of NHEJ or other
error-prone mechanisms of DSB repair acting in their place.
Interestingly, the combinations of base substitution signatures
in BRCA1 and BRCA2 mutant cases are also similar. These
similarities in mutational signatures contrast strikingly with
differences in histology and gene expression profiles between
BRCA1 and BRCA2 mutant cancers (Hedenfalk et al., 2001;
Palacios et al., 2008; Perou et al., 2000; Sørlie et al., 2001). Muta-
tional patterns, which are probably more closely related to the
underlying biological defect, therefore appear to report similari-
ties in disease pathogenesis between BRCA1 and BRCA2
mutant cancers better than cellular phenotype. BRCA1 and
BRCA2 cancers are particularly responsive to some DNA
damaging agents and inhibitors of DNA repair, notably PARP
inhibitors (Fong et al., 2009). Because some breast cancers
without mutations in BRCA1 and BRCA2 are reported to
respond to these treatments (Forster et al., 2011) it will be
interesting to explore whether mutational patterns characteristic
of BRCA1 and BRCA2 null cancers are better predictors of
response to these therapies than the presence of mutations in
the two genes.
These 21 genomes have yielded further evidence of complex
relationships between mutagenesis and transcription. A tran-
scriptional strand bias was found for C>A/G>T mutations in
most of the cancers. If TCR is responsible, DNA damage by bulky
adducts may be implicated in breast cancer pathogenesis. In
principle, these could result from exogenous exposures. Indeed,
many carcinogens cause adducts on guanine. Alternatively, an
exposure could be endogenous in origin, for example reactive
oxygen species (Hori et al., 2011) or intermediates of oxidative
estrogen metabolism (Spencer et al., 2012). Both can cause
damage to guanine and, although preferentially repaired by
BER, some lesions can be substrates for TCR (Hanawalt and
Spivak, 2008). If TCR is not involved, then the data suggest
that other uncharacterized forms of transcription coupled DNA
damage or repair exist.
The relationship between gene expression levels andmutation
prevalence, previously reported in a malignant melanoma and
a small cell lung cancer (Pleasance et al., 2010a; Pleasance
et al., 2010b), has been extended here to primary breast cancers.
The relationship is again inverse in nature, with more somatic
substitutions in poorly expressed genes. The phenom-
enon could, in principle, be due to an increased sensitivity to
DNA damage and/or less efficient repair in poorly expressed
genes. The fact that it applies to the untranscribed strands
of genes and does not correlate with the presence of transcrip-
tional strand bias suggests that these have different underlying
mechanisms. One possibility is that the genome-wide form of
NER is recruited more effectively to highly transcribed genes.
This study has started to untangle and characterize the
mutational processes that contribute to breast cancer. The
data are derived from only 21 genomes and similar analyses of
thousands of cancers by the International Cancer Genome
Consortium (Hudson et al., 2010) will likely yield evidence of
further mutational processes and better definition of those
already known. Nevertheless, the analyses have provided a level
of characterization of mutational processes in cancer that was
previously impossible and illustrate the power of whole cancer
genome sequences, yielding essentially complete catalogs of
somatic mutations, to further understanding of mechanisms of
DNA damage and repair.EXPERIMENTAL PROCEDURES
Samples and Massively Parallel Sequencing
DNA was extracted from 21 breast cancers and normal tissue from the
same individuals. Short insert 500 bp library construction, flowcell pre-
paration and cluster generation were according to the Illumina no-PCR
library protocol (Kozarewa et al., 2009). 108 base or 100 base paired-end
sequencing were performed on Illumina GAIIx or Hiseq 2000 genome
analyzers respectively, as described in the Illumina Genome Analyzer oper-
ating manual.
Short insert 2*108 bp or 2*100 bp paired-end readswere aligned to the refer-
ence human genome (NCBI37) by using BWA (Li and Durbin, 2009). Genome
sequence data have been deposited at the European Genome-Phenome
Archive (http://www.ebi.ac.uk/ega/ at the EBI) with accession number
EGAD00001000138. SNP6 array data have been deposited with ArrayExpress
Archive (EBI, accession number E-MTAB-1087).Mutation-Calling
An in-house bespoke algorithm, CaVEMan was used for calling somatic
substitutions. Insertions and deletions in the tumor and normal genomes
were called by using a modified Pindel version 0.2.0 on the NCBI37 genome
build (Ye et al., 2009). Postprocessing filters were developed to improve
the specificity of mutation-calling. Structural variants were called from the
short insert data by using MAQ alignments as previously described (Campbell
et al., 2008; Stephens et al., 2009). Structural variants in association with
copy number segments were sought to improve sensitivity of detection. Tumor
DNA samples were analyzed by Affymetrix SNP6 microarrays (Bignell et al.,
2010). Copy number and allelic ratio profiles were statistically processed
by using the ASCAT algorithm, version 2.0 (Van Loo et al., 2010). Validation
of substitutions and indels was performed by Roche 454 pyrosequencing
or capillary sequencing. Structural variants were confirmed by custom-
designed PCR across the rearrangement breakpoint or by local sequence
assembly. All confirmations were performed in both tumor and normal.
Gene expression data were derived from the Illumina Human HT12 Expression
BeadChip array, and processed as previously described (Pleasance et al.,
2010a). Somatic mutation data are available via hyperlinks in Table S1B andare also available via COSMIC at http://www.sanger.ac.uk/genetics/CGP/
cosmic/ and have been annotated to Ensembl v58.Statistical Analysis
Mutational processes were extracted by using nonnegative matrix factoriza-
tion. Monte Carlo simulations were performed to assess how randomly
distributed mutations differed to the primary cancer genomes. A Kolmo-
gorov-Smirnov test was used to compare the distribution of indels mediated
by repeats or microhomology.ACCESSION NUMBERS
The EuropeanGenome-Phenome Archive accession number for the sequence
reported in this paper is EGAD00001000138. The ArrayExpress Archive acces-
sion number for the SNP6 array data reported in this paper is E-MTAB-1087.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, three
figures, and one table and can be found with this article online at doi:10.1016/
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